Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 14/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1608123 | 1.00 | RAPGEF4 (0.44) | RAPGEF4ALDH1A1FFAR4NPC1MAPT | |
| Hydrochloric Acid SCHEMBL1608098 | 0.98 | RAPGEF4 (0.43) | RAPGEF4ALDH1A1FFAR4NPC1MAPT | |
| Hydrochloric Acid SCHEMBL1608097 | 0.98 | RAPGEF4 (0.43) | RAPGEF4ALDH1A1FFAR4NPC1MAPT | |
| SCHEMBL16034461 | 0.84 | HTR1D (0.33) | RAPGEF4ALDH1A1 | |
| SCHEMBL16034462 | 0.84 | HTR1D (0.33) | RAPGEF4ALDH1A1 | |
| SCHEMBL16077731 | 0.82 | RAPGEF4 (0.36) | RAPGEF4ALDH1A1 | |
| SCHEMBL1608671 | 0.81 | RAPGEF4 (0.38) | RAPGEF4ALDH1A1SMN1; SMN2 | |
| SCHEMBL11856863 | 0.78 | RAPGEF4 (0.37) | RAPGEF4ALDH1A1 | |
| SCHEMBL9501188 | 0.75 | GRIN2D (0.43) | ALDH1A1 | |
| SCHEMBL9501612 | 0.75 | GRIN2D (0.43) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216900-A1 | SABRE CATALYSTS CONTAINING FLUORINATED CARBON CHAINS FOR DELIVERY OF METAL-FREE MRI CONTRAST AGENTS | THE U.S.A., AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-07-04 | — | — | US | disclosed |
| CN-117551142-A | Organometallic complex, application, organic electroluminescent device and display device | 京东方科技集团股份有限公司 | 2024-02-13 | — | — | CN | disclosed |
| US-9573125-B2 | Functional N-heterocycles for solid-supported catalysis | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2017-02-21 | — | — | US | disclosed |
| EP-2217065-B1 | PREPARATION OF SATURATED IMIDAZOLINIUM SALTS AND RELATED COMPOUNDS | CALIFORNIA INST OF TECHN (US) | 2016-10-12 | — | — | EP | disclosed |
| US-8703965-B2 | Preparation of saturated imidazolinium salts and related compounds | MATERIA, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-20140005036-A1 | FUNCTIONAL N-HETEROCYCLES FOR SOLID-SUPPORTED CATALYSIS | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2014-01-02 | — | — | US | disclosed |
| WO-2011059803-A2 | RUTHENIUM-ALKYLIDENES CONTAINING ACYCLIC DIAMINOCARBENES FOR OBTAINING LOW E/Z RATIOS IN CROSS METATHESIS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-05-19 | — | — | WO | disclosed |
| US-20110087032-A1 | PREPARATION OF SATURATED IMIDAZOLINIUM SALTS AND RELATED COMPOUNDS | MATERIA, INC. (US) | 2011-04-14 | — | — | US | disclosed |
| EP-2217065-A1 | PREPARATION OF SATURATED IMIDAZOLINIUM SALTS AND RELATED COMPOUNDS | Materia, Inc. (US) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009062171-A1 | PREPARATION OF SATURATED IMIDAZOLINIUM SALTS AND RELATED COMPOUNDS | MATERIA, INC. (US) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216900-A1 | SABRE CATALYSTS CONTAINING FLUORINATED CARBON CHAINS FOR DELIVERY OF METAL-FREE MRI CONTRAST AGENTS | FABP7, FFAR1, FABP1 | RAPGEF4 4067/4885ALDH1A1 4484/4885FFAR4 52/4885 |
| US-20110087032-A1 | PREPARATION OF SATURATED IMIDAZOLINIUM SALTS AND RELATED COMPOUNDS | NISCH, INF2, DDT | RAPGEF4 1358/4885ALDH1A1 4255/4885FFAR4 661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.